Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 523 of 6351
-
New hope for advanced breast cancer: drug combo aims to halt tumor growth
Disease control Not yet recruitingThis study aims to evaluate the efficacy of Entinostat combined with Fulvestrant in HR+/HER2- advanced breast cancer patients with recurrence/progression after endocrine therapy (primary endpoint: progression-free survival \[PFS\]), and explore the correlation between peripheral …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could injecting immunotherapy into lymph nodes boost cervical cancer treatment?
Disease control Recruiting nowWe aim to determine feasibility, safety and efficacy of TDLN-targeted immune checkpoint inhibition in different doses (nivolumab) in patients with cervical cancer.
Phase 1 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR-T therapy takes on deadly brain tumors
Disease control Recruiting nowThis is an open-label, single-arm, dose-escalation and expansion Phase 1/2 clinical trial designed to evaluate the safety, tolerability and efficacy of P134 cells in patients with recurrent glioblastoma, to explore the maximum tolerated dose (MTD)and recommended Phase 2 dose (RP2…
Phase 1/2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental CAR-T therapy targets tough childhood leukemia
Disease control CancelledA study to evaluate the safety and preliminary efficacy of CLL-1-targeted CAR-T cell therapy in children aged 3 to 18 years with relapsed or refractory acute myeloid leukemia (r/r AML).
Early phase 1 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New Antibody-Drug conjugate 3H-10000 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThe study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
Phase 1/2 • Sponsor: 3H Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Spinal chemotherapy may block deadly brain cancer spread
Disease control Recruiting nowThe goal of this clinical trial is to test whether adding preventive intrathecal chemotherapy (thiotepa) to the standard Stupp regimen can lower the risk of leptomeningeal metastasis (LM) and extend survival in patients with newly diagnosed glioblastoma (GBM) whose tumors touch t…
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo shows promise in shrinking lung tumors before surgery
Disease control Recruiting nowThis is a single-center, open-label, single-arm phase II exploratory study evaluating a perioperative regimen of iparomlimab and tuvonralimab (QL1706; a bispecific PD-1/CTLA-4 antibody) combined with platinum-based chemotherapy in patients with resectable or potentially resectabl…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a painkiller boost immunotherapy in liver cancer?
Disease control Recruiting nowThis phase II trial tests how well the combination of celecoxib with durvalaumab and tremellimumab works in treating patients with hepatocellular cancer (liver cancer) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (ad…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer subtype
Disease control Recruiting nowThe purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small…
Phase 2/3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug duo aims to tame rare bone marrow cancers
Disease control Recruiting now* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New gene therapy injection shows promise for tough leukemia
Disease control Recruiting nowThis is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 injection for patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Phase 1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Breathalyzer could replace PCR for respiratory infections
Diagnosis Not yet recruitingEmerging respiratory diseases are a global health threat. Viruses such as influenza and coronaviruses have been the main cause of pandemics over the last century. In general, the impact of these respiratory infections is not limited to pandemic risks. Indeed, some pathogens also …
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Can a simple electrical scan spot dangerous lung clots without radiation?
Diagnosis Recruiting nowThis multicenter observational diagnostic study aims to evaluate pulsatile electrical impedance tomography (EIT) for the diagnosis and monitoring of acute pulmonary embolism. The study includes a retrospective phase and a prospective phase. EIT-derived ventilation-perfusion match…
Sponsor: Beijing Tsinghua Chang Gung Hospital • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
New drug could help 'Incompatible' kidney transplants succeed
Disease control Not yet recruitingImlifidase is a recombinant cysteine protease derived from Streptococcus pyogenes and produced in Escherichia coli, which has the ability to cleave and degrade all human IgGs. Four to six hours after imlifidase infusion, the entire IgG pool is degraded into F(ab')2 and Fc fragmen…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo targets lung cancer brain tumors in 60-patient trial
Disease control Not yet recruitingThis multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases. It aims to determine which approach is more effect…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New heart procedure could reduce transplants in End-Stage heart failure patients
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety and efficacy of conduction system pacing (CSP) using left bundle branch pacing (LBBP) and atrioventricular junction (AVJ) ablation in patients with end-stage heart failure and permanent atrial fibrillation (AF). Participants who…
Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo aims to stall lung cancer when targeted pills start to fail
Disease control OngoingThis is a prospective, single-center, Phase II clinical study designed to explore the efficacy and safety of ivonescimab plus third-generation EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer who developed slow progression or potential progression after …
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to boost radiation for tough pancreatic tumors
Disease control Recruiting nowThe purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
Phase 1/2 • Sponsor: Xerient Pharma • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Vacuum-Powered dressing speed up diabetic wound healing?
Disease control CompletedBackground: Diabetic foot ulcers (DFUs) are severe, chronic complications of diabetes carrying a high risk of amputation. While Negative Pressure Wound Therapy (NPWT) is an active biophysical treatment, clinical evidence using multidimensional tools in Middle Eastern settings lik…
Sponsor: Jerash Private University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Cord blood transplant offers new hope for rare EBV diseases
Disease control Recruiting nowThis clinical trial is designed as a single-arm, two-center, open-label, prospective study. All participants are enrolled in the standard-dose unrelated umbilical cord blood transplantation group to evaluate the efficacy and safety of unrelated umbilical cord blood transplantatio…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC